Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation
Identifieur interne : 004B35 ( Main/Exploration ); précédent : 004B34; suivant : 004B36Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation
Auteurs : C. Daubert [France] ; P. Mabo [France] ; D. Gras [France] ; C. Leclerco [France]Source :
- European Heart Journal [ 0195-668X ] ; 1993-11.
English descriptors
- KwdEn :
- Adrenergic beta-Antagonists (therapeutic use), Atrial Fibrillation (drug therapy), Atrial Flutter (drug therapy), Clinical Trials as Topic, Humans, Randomized Controlled Trials as Topic, Sotalol (chemistry), Sotalol (therapeutic use), Stereoisomerism, Tachycardia, Atrioventricular Nodal Reentry (drug therapy), Tachycardia, Supraventricular (drug therapy), Wolff-Parkinson-White Syndrome (drug therapy).
- MESH :
- chemical , chemistry : Sotalol.
- chemical , therapeutic use : Adrenergic beta-Antagonists, Sotalol.
- drug therapy : Atrial Fibrillation, Atrial Flutter, Tachycardia, Atrioventricular Nodal Reentry, Tachycardia, Supraventricular, Wolff-Parkinson-White Syndrome.
- Clinical Trials as Topic, Humans, Randomized Controlled Trials as Topic, Stereoisomerism.
Abstract
Numerous trials performed over the last 20 years, although uncontrolled, have shown the racemic d,l-sotalol is effective for the acute conversion and for long-term prevention of recurrences of supraventricular tachyarrhythmias. Sotalol appeared to be moderately effective in atrial fibrillation or atrial flutter, having somewhat greater efficacy in the case of atrioventricular (AV) nodal re-entrant tachycardia due to Wolff-Parkinson-White syndrome or concealed accessory pathway. These effects may stem from the combined class II and class III electrophysiologic properties of this drug. However, studies comparing d,l-sotalol to pure beta blockers in different ‘models’, especially postsurgical arrhythmias and Wolff-Parkinson-White syndrome, have suggested that the observed clinical benefit may be related to d,l-sotalol's class III properties. Thus, d-sotalol may be efficacious in these indications. Its precise efficacy should be defined in controlled clinical trials.
Url:
DOI: 10.1093/eurheartj/14.suppl_H.67
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001B11
- to stream Istex, to step Curation: 001B09
- to stream Istex, to step Checkpoint: 001B18
- to stream Main, to step Merge: 005536
- to stream PubMed, to step Corpus: 001700
- to stream PubMed, to step Curation: 001659
- to stream PubMed, to step Checkpoint: 001659
- to stream Ncbi, to step Merge: 001C98
- to stream Ncbi, to step Curation: 001C98
- to stream Ncbi, to step Checkpoint: 001C98
- to stream Main, to step Merge: 005507
- to stream Main, to step Curation: 004B35
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation</title><author><name sortKey="Daubert, C" sort="Daubert, C" uniqKey="Daubert C" first="C." last="Daubert">C. Daubert</name></author><author><name sortKey="Mabo, P" sort="Mabo, P" uniqKey="Mabo P" first="P." last="Mabo">P. Mabo</name></author><author><name sortKey="Gras, D" sort="Gras, D" uniqKey="Gras D" first="D." last="Gras">D. Gras</name></author><author><name sortKey="Leclerco, C" sort="Leclerco, C" uniqKey="Leclerco C" first="C." last="Leclerco">C. Leclerco</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E2AE7F383C55138A3F0C592F9BEBD5922363BFDB</idno><date when="1993" year="1993">1993</date><idno type="doi">10.1093/eurheartj/14.suppl_H.67</idno><idno type="url">https://api.istex.fr/document/E2AE7F383C55138A3F0C592F9BEBD5922363BFDB/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001B11</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001B11</idno><idno type="wicri:Area/Istex/Curation">001B09</idno><idno type="wicri:Area/Istex/Checkpoint">001B18</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001B18</idno><idno type="wicri:doubleKey">0195-668X:1993:Daubert C:clinical:role:of</idno><idno type="wicri:Area/Main/Merge">005536</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:7904939</idno><idno type="wicri:Area/PubMed/Corpus">001700</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001700</idno><idno type="wicri:Area/PubMed/Curation">001659</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001659</idno><idno type="wicri:Area/PubMed/Checkpoint">001659</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001659</idno><idno type="wicri:Area/Ncbi/Merge">001C98</idno><idno type="wicri:Area/Ncbi/Curation">001C98</idno><idno type="wicri:Area/Ncbi/Checkpoint">001C98</idno><idno type="wicri:doubleKey">0195-668X:1993:Daubert C:clinical:role:of</idno><idno type="wicri:Area/Main/Merge">005507</idno><idno type="wicri:Area/Main/Curation">004B35</idno><idno type="wicri:Area/Main/Exploration">004B35</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation</title><author><name sortKey="Daubert, C" sort="Daubert, C" uniqKey="Daubert C" first="C." last="Daubert">C. Daubert</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Mabo, P" sort="Mabo, P" uniqKey="Mabo P" first="P." last="Mabo">P. Mabo</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Gras, D" sort="Gras, D" uniqKey="Gras D" first="D." last="Gras">D. Gras</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Leclerco, C" sort="Leclerco, C" uniqKey="Leclerco C" first="C." last="Leclerco">C. Leclerco</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">European Heart Journal</title><idno type="ISSN">0195-668X</idno><idno type="eISSN">1522-9645</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="1993-11">1993-11</date><biblScope unit="volume">14</biblScope><biblScope unit="supplement">suppl_H</biblScope><biblScope unit="page" from="67">67</biblScope><biblScope unit="page" to="73">73</biblScope></imprint><idno type="ISSN">0195-668X</idno></series><idno type="istex">E2AE7F383C55138A3F0C592F9BEBD5922363BFDB</idno><idno type="DOI">10.1093/eurheartj/14.suppl_H.67</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0195-668X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenergic beta-Antagonists (therapeutic use)</term><term>Atrial Fibrillation (drug therapy)</term><term>Atrial Flutter (drug therapy)</term><term>Clinical Trials as Topic</term><term>Humans</term><term>Randomized Controlled Trials as Topic</term><term>Sotalol (chemistry)</term><term>Sotalol (therapeutic use)</term><term>Stereoisomerism</term><term>Tachycardia, Atrioventricular Nodal Reentry (drug therapy)</term><term>Tachycardia, Supraventricular (drug therapy)</term><term>Wolff-Parkinson-White Syndrome (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Sotalol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenergic beta-Antagonists</term><term>Sotalol</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Atrial Fibrillation</term><term>Atrial Flutter</term><term>Tachycardia, Atrioventricular Nodal Reentry</term><term>Tachycardia, Supraventricular</term><term>Wolff-Parkinson-White Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term><term>Humans</term><term>Randomized Controlled Trials as Topic</term><term>Stereoisomerism</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">Numerous trials performed over the last 20 years, although uncontrolled, have shown the racemic d,l-sotalol is effective for the acute conversion and for long-term prevention of recurrences of supraventricular tachyarrhythmias. Sotalol appeared to be moderately effective in atrial fibrillation or atrial flutter, having somewhat greater efficacy in the case of atrioventricular (AV) nodal re-entrant tachycardia due to Wolff-Parkinson-White syndrome or concealed accessory pathway. These effects may stem from the combined class II and class III electrophysiologic properties of this drug. However, studies comparing d,l-sotalol to pure beta blockers in different ‘models’, especially postsurgical arrhythmias and Wolff-Parkinson-White syndrome, have suggested that the observed clinical benefit may be related to d,l-sotalol's class III properties. Thus, d-sotalol may be efficacious in these indications. Its precise efficacy should be defined in controlled clinical trials.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Région Bretagne</li></region><settlement><li>Rennes</li></settlement></list><tree><country name="France"><region name="Région Bretagne"><name sortKey="Daubert, C" sort="Daubert, C" uniqKey="Daubert C" first="C." last="Daubert">C. Daubert</name></region><name sortKey="Gras, D" sort="Gras, D" uniqKey="Gras D" first="D." last="Gras">D. Gras</name><name sortKey="Leclerco, C" sort="Leclerco, C" uniqKey="Leclerco C" first="C." last="Leclerco">C. Leclerco</name><name sortKey="Mabo, P" sort="Mabo, P" uniqKey="Mabo P" first="P." last="Mabo">P. Mabo</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004B35 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004B35 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:E2AE7F383C55138A3F0C592F9BEBD5922363BFDB
|texte= Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation
}}
| This area was generated with Dilib version V0.6.29. |  |